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Aortic Valve Replacement
With great interest we read the recent report by Reynolds et al. (1)
reporting on the health-related quality-of-life (HRQOL) out-
comes in Cohort A of the PARTNER (Placement of Aortic
Transcatheter Valves) randomized controlled trial. Using 3 differ-
ent standardized questionnaires at 1, 6, and 12 months, HRQOL
was analyzed in a total of 628 patients with severe, symptomatic
aortic valve stenosis at high surgical risk who were randomized to
transcatheter aortic valve replacement (TAVR) via the transapical
or transfemoral approach or to surgical aortic valve replacement
(SAVR). Health status improved substantially between baseline
and 1 year after both TAVR and SAVR. TAVR via the trans-
femoral but not the transapical route was associated with short-
term advantages compared with surgery. Although evidence is
accumulating that patients at high risk for SAVR undergoing
TAVR derive HRQOL benefits, the investigators should be
commended for this important study, because it represents the first
randomized study investigating HRQOL dynamics after TAVR in
comparison with SAVR, adding an important piece of evidence to
the field.
We would greatly appreciate the investigators’ comments on
how New York Heart Association functional class developed over
time. As long as valve function is durable, one would expect that
functional benefits can be maintained in the longer term as well.
However, data derived from Cohort B of the PARTNER trial and
other studies suggest that functional status slightly worsens at 12
months (2–4). We concur with the investigators that the results of
available studies encompass only a maximal follow-up period of 1
year, which may be too short. Therefore, the longer term dynamics
of HRQOL changes in TAVR patients remain elusive.
Did the investigators attempt to evaluate and correlate
HRQOL outcomes with New York Heart Association functional
class or with any of the baseline characteristics? The identification
of patient-related or procedure-related parameters predictive of the
extent of HRQOL benefits would be highly desirable to facilitate
better risk stratification and patient selection and to improve
guidance of patient-centered clinical decision making. It has been
observed that the extent of benefit seems to be inferior for patients
with oxygen-dependent chronic obstructive pulmonary disease (2).
Also, lower operator experience, female sex, and vascular compli-
cations have been reported to be independent predictors of lower
HRQOL improvements at 1 year (3). In our prospective cohort,
mitral valve regurgitation I° was predictive of lower HRQOL
improvements. Only at 3 months did this association reach
statistical significance. Likewise, female sex was associated with
less improvement at 3 months, corroborating the results described
by Fairbairn et al. (3). Notably, we could not observe anyassociation with Society of Thoracic Surgeons score or log Euro-
pean System for Cardiac Operative Risk Evaluation score, hemo-
dynamic parameters, or comorbidities (4).
Larger patient numbers in conjunction with longer follow-up
will be necessary to identify reliable patient-related and procedure-
related factors predictive of the extent of HRQOL benefits and to
answer the question of whether benefits are durable conclusively.
In the future, it will be of interest to determine how HRQOL
benefits compare between TAVR and SAVR in patients at lower
surgical risk (5).
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Reply
We agree with many of the points raised in the letter by Dr.
Deutsch and colleagues and appreciate their interest in our work.
We have not as yet made any formal correlations between
patient-level health status measures and New York Heart Associ-
